返回 
加入收藏
康艾注射液辅助化疗治疗晚期肺癌的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 康艾注射液辅助化疗治疗晚期肺癌的临床观察 |
| TITLE： | |
| 摘要： | 目的：探讨康艾注射液辅助化疗治疗晚期肺癌的临床疗效及安全性。方法：选取2013年5月－2014年4月晚期肺癌患者146例，根据入院单双号分为观察组和对照组，各73例。对照组患者给予GP（吉西他滨+顺铂）方案化疗；观察组患者在对照组基础上加用康艾注射液60 mL加入生理盐水250 mL中， qd，ivgtt，每个化疗周期连用14 d。两组患者化疗期间均采用托烷司琼5 mg预防胃肠道反应。3周为一个疗程，两组患者均治疗3个疗程。比较两组患者临床疗效及治疗前后血清炎性因子[超敏C反应蛋白（hs-CRP）、肿瘤坏死因子α（TNF-α）、干扰素γ（IFN-γ）、白细胞介素10 （IL-10）]、免疫功能指标（CD3+、CD4+、CD8+、CD4+/CD8+）、肿瘤标志物[鳞状细胞癌相关抗原（SCC-Ag）、癌胚抗原（CEA）、糖类抗原（CA）50、CA72-4]水平，并记录不良反应发生情况。结果：观察组患者的临床有效率、疾病控制率分别为39.73％、84.93％，显著高于对照组的23.29％、71.23％，差异均有统计学意义（P＜0.05）。治疗前，两组患者血清炎性因子、免疫指标、肿瘤标志物水平比较，差异均无统计学意义（P＞0.05）；治疗后，两组患者hs-CRP、TNF-a、INF-γ水平均显著低于治疗前，IL-10显著高于治疗前，且观察组上述指标均显著优于于对照组，差异均有统计学意义（P＜0.05）；对照组CD4+、CD4+/CD8+水平显示降低，且显著低于观察组，差异均有统计学意义（P＜0.05）；两组患者血清SCC-Ag、CEA、CA50、CA72-4水平均显著降低，且观察组显著低于对照组，差异均有统计学意义（P＜0.05）。观察组患者血小板减少、中性粒细胞减少、肝功能异常、恶心呕吐、贫血的发生率均显著低于对照组，差异均有统计学意义（P＜0.05）。结论：康艾注射液辅助化疗能有效缓解晚期肺癌患者的炎症状态，减轻毒副反应，增强免疫功能，提高近期疗效，且安全性较高。 |
| ABSTRACT： | OBJECTIVE： To investigate clinical efficacy and safety of Kang’ai injection adjuvant chemotherapy for advanced lung cancer. METHODS： A total of 146 patients with advanced lung cancer during May 2013-Apr. 2014 were divided into observation group and control group according to odd-even admission number， with 73 cases in each group. Control group was given GP （gemcitabine+cisplatin） chemotherapy. Observation group was additionally given Kang’ai injection 60 mL added into normal saline 250 mL， qd， ivgtt， for consecutive 14 d each chemotherapy cycle， on the basis of control group. Both groups were given tropisetron 5 mg for preventing gastrointestinal reaction during chemotherapy. A treatment course lasted for 3 weeks， and both groups were treated for 3 courses. Clinical efficacies of 2 groups were compared； the levels of serum inflammatory factors （hs-CRP， TNF-α， IFN-γ， IL-10）， immune function indexes （CD3+， CD4+， CD8+， CD4+/CD8+） and tumor markers （SCC-Ag， CEA， CA50， CA72-4） were compared before and after treatment. The occurrence of ADR were recorded in 2 groups. RESULTS： The response rate and disease control rate of observation group were 39.73％ and 84.93％， which were significantly higher than 23.29％ and 71.23％ of control group， with statistical significance （P＜0.05）. Before treatment， there was no statistical significance in the levels of serum inflammatory factors， immune function indexes or tumor markers between 2 groups （P＞0.05）. After treatment， the levels of hs-CRP， TNF-α and IFN-γ in 2 groups were significantly lower than before treatment， while the level of IL-10 was significantly higher than before treatment； above indexes of observation group were significantly better than control group， with statistical significance （P＜0.05）. The levels of CD4+ and CD4+/CD8+ in control group were decreased significantly and lower than observation group， with statistical significance （P＜0.05）. Serum levels of SCC-Ag， CEA， CA50 and CA72-4 in 2 groups were decreased significantly， and observation group was significantly lower than control group， with statistical significance（P＜0.05）. The incidence of thrombocytopenia， neutropenia， abnormal liver function， nausea and vomiting， anemia in observation group were significantly lower than control group， with statistical significance （P＜0.05）. CONCLUSIONS： Kang’ai injection adjuvant chemotherapy can effectively relieve inflammation symptoms of patients with advanced lung cancer， reduce toxic reactions， enhance immune function， and improve short-term therapeutic efficacy with good safety. |
| 期刊： | 2017年第28卷第35期 |
| 作者： | 路颜增，谭柏清，孙东平，罗维晓 |
| AUTHORS： | LU Yanzeng，TAN Baiqing，SUN Dongping，LUO Weixiao |
| 关键字： | 晚期肺癌；康艾注射液；炎性因子；免疫功能；肿瘤标志物 |
| KEYWORDS： | Advanced lung cancer； Kang’ai injection； Inflammatory factors； Immune function； Tumor markers |
| 阅读数： | 350 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
